Daré Bioscience ( (DARE) ) has issued an announcement.
Daré Bioscience has secured a $10 million milestone-based funding from the ARPA-H Sprint for Women’s Health to advance DARE-HPV, an innovative treatment for HPV-related cervical diseases. This project aims to develop the first FDA-approved non-surgical treatment for high-grade cervical lesions, potentially revolutionizing HPV management. The funding underscores the urgency to address HPV, a leading cause of cervical cancer, and could transform treatment practices with a focus on women’s health.
For detailed information about DARE stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
